CAS No. |
1207753-03-4 |
中文名称 |
((1S,2R,3R,4aR,6aS,7R,8R,10aR,10bR,12aR,12bR)-2-((R)-2-氨基-2,3,3-三甲基丁氧基)-1,6a,8,10a-四甲基-8-((R)-3-甲基丁烷-2-基)-3-(5-(吡啶-4-基)-1H-1,2,4-三唑-1-基)-1,3,4,6,6a,7,8,9,10,10a,10b,11,12,12a-十四氢-2H-1,4a-(甲撑氧甲撑)屈-7-羧酸) |
英文名称 |
(1S,2R,3R,4aR,6aS,7R,8R,10aR,10bR,12aR)-2-((R)-2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8-((R)-3-methylbutan-2-yl)-3-(5-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1,3,4,6,6a,7,8,9,10,10a,10b,11,12,12a-tetradecahydro-2H-1,4a-(methanooxymethano)chrysene-7-carboxylic acid |
别名 |
Ibrexafungerp | AKOS032946516 | ibrexafungerpum | Ibrexafungerp [USAN] | (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2-dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,1 |
标准英文名 |
(1S,2R,3R,4aR,6aS,7R,8R,10aR,10bR,12aR)-2-((R)-2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8-((R)-3-methylbutan-2-yl)-3-(5-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1,3,4,6,6a,7,8,9,10,10a,10b,11,12,12a-tetradecahydro-2H-1,4a-(methanooxymethano)chrysene-7-carboxylic acid |
分子式 |
C44H67N5O4 |
分子量 |
730.05
|
精确分子量 |
729.52
|
SMILES |
CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(COC[C@@]4(C)[C@@H](OC[C@](C)(N)C(C)(C)C)[C@H](N4N=CN=C4C4=CC=NC=C4)C5)C3=CC[C@@]2(C)[C@@H]1C(=O)O |
标准SMILES |
CC(C)(C)[C@@](C)(N)CO[C@H]1[C@@H](C[C@@]23COC[C@]1(C)[C@@H]2CC[C@H]1C3=CC[C@@]2(C)[C@H](C(O)=O)[C@](C)(CC[C@@]21C)[C@H](C)C(C)C)N1N=CN=C1C1C=CN=CC=1 |
用途 |
Ibrexafungerp is approved by the FDA for the treatment of vulvovaginal candidiasis (VVC) in adult and post-menarchal pediatric females; it exhibits potent broad-spectrum antifungal activity against fungal strains resistant to conventional antifungal agents such as azoles or echinocandins. |
InChIKey |
BODYFEUFKHPRCK-ZCZMVWJSSA-N |